Chapter 60: Metabolic Disorders

Obesity is characterized as a chronic endocrinological and metabolic disease involving excessive adipose tissue accumulation and dysfunction, classified primarily through body mass index measurements into categories ranging from overweight through severe obesity. The condition results from complex interactions between genetic predisposition, neuroendocrinological regulation of appetite through hormones such as ghrelin and leptin, environmental factors including dietary patterns and physical activity levels, and emerging evidence regarding gut microbiome alterations. Clinical management adopts a multidisciplinary approach targeting metabolic improvement rather than cosmetic outcomes, with initial weight loss goals of five to ten percent over six months demonstrating meaningful health benefits. Therapeutic strategies incorporate dietary modifications emphasizing plant-based whole foods, aerobic exercise recommendations of at least one hundred fifty minutes weekly, pharmacological interventions including lipase inhibitors and appetite suppressants that target various metabolic pathways, and bariatric surgical procedures reserved for patients meeting specific body mass index criteria who have not responded to conventional approaches. Gout represents an inflammatory crystal-induced arthropathy precipitated by hyperuricemia and the subsequent deposition of monosodium urate crystals within joints and surrounding tissues. The condition progresses through distinct stages including asymptomatic periods with microscopic crystal formation, acute inflammatory episodes characterized by excruciating pain particularly in the first metatarsophalangeal joint, intercritical intervals of symptom resolution, and chronic tophaceous manifestations featuring nodular urate deposits and potential joint damage. Diagnostic confirmation requires microscopic identification of needle-shaped negatively birefringent urate crystals in synovial fluid aspirates, supported by elevated serum uric acid levels and characteristic radiographic findings. Acute management focuses on rapidly terminating inflammation through nonsteroidal anti-inflammatory agents, colchicine therapy initiated within thirty-six hours of symptom onset, or corticosteroids for refractory presentations, while long-term prevention employs urate-lowering therapies including xanthine oxidase inhibitors, uricosuric agents, and recombinant uricase for treatment-resistant cases, supplemented by dietary restrictions on purine-containing foods and increased fluid consumption.